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The GLI transcription factors mediate the hedgehog signal in development and carcinogenesis. Basal cell carcinoma can be caused by
overexpression of either GLI1 or GLI2. Though GLI1 and GLI2 have identical or very similar DNA binding specificities, some of their activities
are overlapping, some are clearly distinct. We analyzed target gene specificities of GLI1 and constitutively active GLI2 (GLI2ΔN) by global
expression profiling in an inducible, well-characterized HaCaT keratinocyte expression system. Four hundred fifty-six genes up- or downregulated
at least twofold were identified. GLI target gene profiles correlated well with the biological activities of these transcription factors in hair follicles
and basal cell carcinoma. Upregulation of largely overlapping sets of target genes was effected by both factors, repression occurred predominantly
in response to GLI2. Also, significant quantitative differences in response to GLI1 and GLI2ΔN were found for a small number of activated genes.
Since we have not detected a putative processed GLI2 repressor, these results point to specific but indirect target gene repression by GLI2ΔN via
preferential activation of one or more negative regulators.
© 2005 Elsevier Inc. All rights reserved.Keywords: Basal cell carcinoma; GLI target genes; Global expression analysis; Keratinocytes; Transcriptional repressionThe hedgehog (Hh) signaling pathway (reviewed in [1,2])
has been implicated not only in development, but also in the
formation and maintenance of different tumors of skin, brain,
prostate, upper gastrointestinal tract, and lung (reviewed in [3–
8]). The tumorigenic effect of constitutive hedgehog signaling
was first demonstrated in basal cell carcinoma (BCC), in which
the majority of tumors are caused by the inactivation of the Hh
receptor and negative pathway regulator PTCH [9–11]. In
addition, mutations in SMOH leading to constitutive pathway
activation have been found in sporadic BCC [12,13]. Pathway
activation by overexpression of Sonic hedgehog (SHH) in
human keratinocytes or mouse skin also leads to BCC-like
features and changes in gene expression [14,15]. The zinc finger
transcription factors GLI1 and GLI2, the main mediators of the
hedgehog signal in skin, can both cause epithelial tumors with
characteristics of BCC when overexpressed in the basal⁎ Corresponding author. Fax: +43 662 8044 183.
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doi:10.1016/j.ygeno.2005.12.003epidermal layer and the outer root sheath of the hair follicle in
transgenic mice and frog skin [16–20]. Overlapping function
between GLI1 and GLI2 in development, however, is apparent
from the different phenotypes of single and compound mutants
[21–27] and has most clearly been demonstrated by the rescue
of the Gli2−/− developmental phenotype in mice expressing
Gli1 from the Gli2 locus, except for a subtle, unexplained skin
phenotype [28]. GLI1 and GLI2 have been shown to have
distinct as well as overlapping functions. Though GLI1 has
been shown to have activator functions only [29–32], GLI2 can
clearly act as an activator as proven by the substitution
experiment referred to above, but there is also evidence for
repressive function of GLI2 [24,30,32–34]. Differences in the
biological activities of Gli1 and Gli2 exist, since Gli1−/− mice
have no obvious phenotype, while homozygous Gli2−/− mice
die around birth and have abnormal lungs and neural tube and
also defects in hair follicle development [21,27,35,36].
Data on the respective roles of GLI1 and GLI2 in
tumorigenesis are less extensive. Using a conditional Gli2
allele Hutchin et al. [37] showed that BCC-like tumor growth
617T. Eichberger et al. / Genomics 87 (2006) 616–632and maintenance depend on continuous expression of Gli2 in
tumor cells. GLI1 is the hedgehog target gene most consistently
expressed at elevated levels in BCC and in the majority—if not
all—Hh-associated tumors [16,38,39]. GLI1 has been shown to
be important in growth and maintenance of prostate tumor cells
[38,40]. GLI1 is also likely to play a critical role in
medulloblastoma, where it is highly expressed. In Gli1−/−
mice the incidence of medulloblastoma caused by constitutive
Hh signaling [41] is severely reduced even though it can occur.
Less is known about the role of GLI2 in Hh signaling-induced
tumors.
To define the relative contributions of these transcription
factors to carcinogenesis, we focused on basal cell carcinoma,
where the action of GLI1 or GLI2 is sufficient to give rise to
tumors. To assess on a molecular level the extent of
overlapping and distinct target gene specificities of GLI1
and GLI2, we used conditional expression in the human
keratinocyte cell line HaCaT [42], in whic h we have
previously shown that (i) the response to GLI1 and GLI2 is
similar to that of primary human keratinocytes and (ii) GLI1
and GLI2 can elicit expression patterns that resemble to a
significant extent those of BCC [43]. Here, we have
addressed by global expression profiling and QRT-PCR the
target gene specificities of the transcriptional activators GLI1
and GLI2ΔN, a constitutively active form of GLI2 lacking
the N-terminal repression domain [44]. Human full-length
GLI2 was recently described by Roessler and colleagues [34]
and shows significantly lower transcriptional activator func-
tion than GLI2ΔN in vitro. In vivo, in mouse hair follicle
development, there is evidence that full activation of Gli2
depends on an event that requires the presence of Shh. In the
absence of Shh, rescue of the phenotype can be achieved only
by a constitutively active, N-terminally truncated Gli2 protein
that closely resembles the human GLI2ΔN [36]. Similarly,
only truncated/activated Gli2 is able to mimic Shh-induced
gene expression in isolated presomitic mesoderm [24,30]. N-
terminally truncated Gli2 has also been shown to produce a
more severe tumor phenotype than full-length Gli2 when
expressed in the epidermis of transgenic mice [19]. The
truncated human GLI2, GLI2ΔN, is therefore a valuable tool
to mimic the activated form of GLI2. When we used DNA-
array technology to analyze the transcription profiles induced
by conditionally expressed GLI2ΔN and GLI1, we identified
qualitative and quantitative similarities as well as differences
in their target gene response. Only very few genes were
upregulated exclusively by either GLI1 or GLI2ΔN. The most
striking difference between GLI1 and GLI2ΔN was the very
small number of genes repressed on induction of GLI1, while
a large number were repressed after induction of GLI2ΔN. In
the absence of evidence for proteolytic processing and in
view of the strongly activating properties of GLI2ΔN,
repression of target genes in this system is likely to be
indirect, possibly by GLI2 specific activation of a repressor.
The data provide evidence for selective activation of
transcriptional programs by GLI1 and GLI2, which could
have significant consequences for the execution of the
hedgehog signal in keratinocytes.Results and discussion
Differential induction and repression of GLI1 and GLI2 target
genes
To compare GLI1 and GLI2 expression profiles in
keratinocytes we used tetracycline-inducible HaCaT cell lines
expressing GLI1 or an activated form of GLI2 (GLI2ΔN) [43].
To minimize cell clone-specific effects we pooled four inde-
pendent clones. Since a comparison of the relative effects of
GLI1 and GLI2ΔN has to be based on similar expression levels
of the transcription factors, we first measured transgene
expression by QRT-PCR at the RNA level. Both GLI1 and
GLI2ΔN were expressed at comparable levels in the induced
cells used for the expression analysis (Fig. 1A). Fig. 1A shows
that the increase in PTCH mRNA reflects the increase in GLI1
and GLI2ΔN mRNA levels, implying similar transcriptional
activity of both GLI proteins. We also demonstrated induction
of GLI1 and GLI2ΔN by Western blot (Fig. 1A, top). To
compare activity and specificity of GLI1, GLI2ΔN, and the
newly described full-length GLI2 [34], we used luciferase
assays on three different promoters: the known target genes
PTCH [45] (C. Schmid, unpublished) and GLI1 [46] and an
artificial promoter containing six tandem GLI binding sites [47]
(Fig. 1B). Activation of all three promoters is strongest with
GLI2ΔN, followed by GLI1 and full-length GLI2. The relative
activities of the three GLI proteins, however, vary widely on the
three tested promoters. Differential activity of different GLI
proteins on different promoters is frequently observed and may
be partly responsible for different effects of the transcription
factors as discussed below.
Approximately 12,000 PCR-amplified, sequence-verified
EST clones on high-density filter arrays were hybridized with
33P-labeled cDNA from GLI1- or GLI2ΔN-expressing and
control cells to determine expression levels after 24 and 72
h of tetracycline treatment (see Material and methods). In
total, RNA levels of 456 genes represented by 512 EST
clones were found to be increased or decreased at least
twofold at one or both time points as judged by SAM
(significance analysis of microarray) [48] (Table 1). Fig. 2
compares the inducing and repressing activities of GLI1 and
GLI2ΔN. Seventy-two hours after induction 68 genes were
induced more than twofold by GLI1 and 138 by GLI2ΔN, 46
of these were induced by both. Most genes upregulated by
GLI2ΔN were also upregulated by GLI1. The smaller number
of genes responding to GLI1 than GLI2ΔN may reflect the
fact that for many genes the strength of the response was
higher for GLI2ΔN than for GLI1. For a very small number
of genes there is such a large difference between the
activation by the two transcription factors that expression of
those genes can be considered specific to just GLI1 or GLI2.
For GLI2 induction of BCL2 such specificity has previously
been described [49]. Here we find GLI2 specificity also for
FST, while TNC and CTSL are much more strongly activated
by GLI1 than by GLI2ΔN (Table 1 and Fig. 5). It is possible
that a gene-specific threshold of GLI activity is required, but
the detailed mechanism is not known.
Fig. 1. Transcriptional activity of GLI1 or GLI2ΔN in HaCaT keratinocytes. (A)
The induction in HaCaT cells of GLI1 and GLI2ΔN under tetracycline control
was determined by QRT-PCR and Western blot. Increase of the GLI1 or
GLI2ΔN transgene and the direct target gene PTCH mRNAs is shown after
induction for the times indicated. GLI1 and GLI2ΔN proteins (top) were
detected using specific antibodies against GLI1 and GLI2. Samples were taken
from tetracycline-treated and untreated double stable HaCaT cells as indicated.
(B) Luciferase reporter assay comparing the activities of GLI1, GLI2ΔN, and
human full-length GLI2 on different promoter constructs. HaCaT cells were
cotransfected with different reporter constructs (the synthetic reporter construct
6×GLIbs, PTCHprom, and GLI1prom) and NLS-Myc-tagged GLI1 (GLI1),
Myc-tagged GLI2ΔN (GLI2ΔN), Myc-tagged full-length GLI2 (GLI2), or
empty expression vector (pc).
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clones after 72 h of tetracycline treatment by GLI1 compared to
190 genes for GLI2ΔN; 28 of these were repressed by both. The
results are even more striking at the 24-h time point, at which
twice as many genes were induced, but 17 times as many
repressed by GLI2ΔN compared to GLI1. A large majority of
genes repressed by GLI2ΔN are not affected by GLI1, whileonly a very small number of genes repressed in response to
GLI1 are unaffected by GLI2ΔN expression. Most genes
repressed by GLI1 are also repressed by GLI2ΔN. Since in
GLI1-expressing HaCaT cells endogenous GLI2 is also turned
on after a delay [43], it is not possible to discriminate between a
specific effect of GLI1 and an indirect effect via GLI1-induced
expression of endogenous GLI2. These results show a clear
difference between the regulatory effects of GLI1 and GLI2ΔN
in keratinocytes compatible with in vivo data in other systems
showing only activating function for Gli1, but activating and
repressing function for Gli2 [24,30,32–34]. It is surprising that
repression can take place in the absence of the putative N-
terminal repressor domain of GLI2 [30,34]. The data, however,
do not address whether repression of target genes is caused
directly by a GLI2 repressor function present also in GLI2ΔN
or indirectly by GLI2-mediated induction of an unknown
repressor activity. Ci, the single Drosophila ortholog of the
three mammalian GLI transcription factors, can act either as
activator or as repressor of transcription. In the presence of Hh,
an activated form of full-length 155-kDa Ci induces the
expression of Hh target genes, while in the absence of Hh a
proteolytically processed 75-kDa repressor form is localized to
the nucleus and prevents the expression of Hh target genes
(reviewed in [1,2]). Of the three mammalian GLI proteins [50],
mouse Gli1 has been described as having only activating
functions, which can be supplied also by mouse Gli2 [21,28].
Mouse Gli3 is an important repressor of Hh target genes in limb
and neural development [51,52], but also has an activating
function [24,53]. In vitro, all three GLI proteins have been
shown to be able to act as dominant negative, if the protein is
truncated C-terminally to the Zn-finger DNA binding domain
[23,30,32,54], indicating the presence of activating domains in
the deleted fragment. The structure of these molecules is similar
to that of the in vivo-processed 75-kDa repressor form of Ci
[23,32].
The repressor activity of C-terminally truncated Gli3 has
been amply demonstrated in vivo and in vitro [23,51,54,55].
The in vivo repressor role of a corresponding truncated Gli2
protein is much less clear. Unlike Gli3, the repressing activity of
Gli2 observed in some contexts is not responsive to the Hh
signal. Truncated products of Gli2 have been observed after
expression in frog embryos [23], COS cells [51], and
Drosophila melanogaster [32], but there is no clear evidence
for such a repressor form in the absence of ectopic
overexpression.
Phosphorylation by protein kinase A (PKA) is a precondi-
tion for proteolytic processing of Ci and of Gli3 to a C-
terminally truncated form with repressor activity [23,56–58].
In the expression analysis the large number of genes repressed
in response to GLI2ΔN could arise due to either direct
repression by a modified form of GLI2ΔN or another
mechanism. We therefore first assayed for forskolin-induced
PKA phosphorylation of the GLI proteins by immunoprecip-
itation using GLI1- and GLI2ΔN-specific antibodies followed
by detection using PKA substrate-specific antibody (Fig. 3A).
We then looked for the appearance of proteolytically processed
forms of the GLI proteins in Western blots of whole lysates
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length specific fragments were detected (Fig. 3B). We therefore
conclude that detectable processing of the inducible GLI2ΔN
protein in a way comparable to that of Ci or GLI3 does not
occur in HaCaT cells even though strong repression of target
genes is observed.
Groups of functionally related genes regulated by GLI1 and
GLI2
Based on their molecular function and association with
pathways, we grouped the differentially expressed genes
according to gene map classification using Pathway Explorer
(https://www.pathwayexplorer.genome.tugraz.at/) [59] (Fig. 4
and Table 1). As expected, cell cycle and proliferation are among
the most highly represented classes. Two pathways known to
interact with HH, WNTand TGFβ, also appear. These and other
classes are discussed below in the context of skin, BCC, and hair
follicles.
To verify a subset of the array data we used QRT-PCR (genes
marked by superscript “b” in Table 1). For selected genes we
refined the time resolution by a 12-h point (Fig. 5 and Table 2).
The QRT-PCR data show good agreement with the array data for
kinetics and level of induction. The higher fold-change values
measured by QRT-PCR are a common phenomenon, likely to be
due to the higher dynamic range of the PCR-based approach.
We have previously shown that GLI2ΔN induces the
expression of genes driving proliferation and represses
epidermal differentiation markers [60]. We now compared
these results to the GLI1 response and observed very little
repression of differentiation markers such as KRT1, KRT10,
IVL, SPRR2A (Table 2, bottom), DSG1, S100A8, and S100A9
(Table 1), while genes involved in promoting proliferation were
induced also by GLI1 (Table 2, top), illustrating the distinct and
overlapping specificities of the effects of the two related
transcription factors. Cell cycle genes regulated by GLI1 and
GLI2ΔN include some cyclins, cyclin inhibitors, cyclin-
dependent kinases, and other proteins involved in critical
steps of cell cycle progression such as E2F1. Increased cell
cycle progression is also seen in the mRNA increase of the
classical markers MKI67 (Ki67), PCNA, and MAD2L1 (Table
1), a mitotic checkpoint protein induced by E2F1 [61].
Differential expression in response to GLI1 or GLI2ΔN
was also found for different proteases and their inhibitors,
though this does not necessarily correlate with their activity
since protease activity is mostly regulated at the posttransla-
tional level. Of the members of the kallikrein family of serine
proteases expressed in skin, KLK6 was highly and KLK5 and
KLK10 were moderately induced by both GLI1 and GLI2ΔN
(Fig. 5A). The serine protease inhibitor Kazal-type 5
(SPINK5) (Table 1), which is coexpressed with kallikrein
proteases in skin, is downregulated by GLI2ΔN only.
Expression of several other serine protease inhibitors is also
changed by GLI expression: SERPINA1 and SERPINB2 are
upregulated, while SERPINB3, SERPINB5, and SERPINB13
are turned down, as is the epithelial-specific protease inhibitor
PI3 (SKALP/elafin) (Fig. 5D and Table 1). An example of thecomplementary regulatory roles of GLI1 and GLI2ΔN is the
lysosomal cysteine protease cathepsin L (CTSL), which is also
expressed in skin and hair follicles. CTSL is upregulated in
response to GLI1 and to a lower extent by GLI2ΔN, while its
inhibitor cystatin A (CSTA) is downregulated by GLI2ΔN
only (Figs. 5B and 5D). The metalloproteases illustrate
opposite effects in successive regulatory steps: MMP1,
MMP10, MMP12, and MMP13 show a strong negative
response to GLI2ΔN and a weaker one to GLI1 expression
(Table 1). From the higher time resolution of the QRT-PCR
analysis for MMP1, MMP10, and MMP13 it is clear that
repression is reversed at the 72-h time point (Fig. 5D, inset).
This is likely to be mediated by the transcription factor
FOXE1, a direct target gene of GLI2 [62], which strongly
induces expression of these MMPs when expressed in HaCaT
keratinocytes (data not shown).
GLI2ΔN plays an essential role in hair follicle development
[36] and is highly expressed in the outer root sheath (ORS) [46].
We found significant similarities between genes expressed in
hair follicles and HaCaT cells expressing GLI2ΔN. BCCs are
another structure expressing GLI target genes. Some genes
expressed in the ORS and in BCCs are upregulated by GLI2ΔN
in HaCaT cells (CTSL, FOXE1, BCL2) (Fig. 5C), while most of
the downregulated genes (KRT1, KRT10, IVL, DSG1) (Fig. 5D
and Table 1) are not normally present in the basal layer of
epidermis, the ORS, and BCCs. The protease CTSL (see above)
has also been localized to the ORS. Its importance in proper
skin and hair morphology is underlined by the phenotype of
CTSL-deficient mice, which develop epidermal hyperplasia,
acanthosis, hyperkeratosis, and periodic hair loss [63–65].
CTSL is also elevated in BCC [66]. An important role in
development and cycling of the hair follicle and skin
homeostasis involves TGFβ signaling. Members of the TGFβ
family are involved in the control of keratinocyte proliferation
and differentiation during normal skin stratification (reviewed
in [67–69]). We found upregulation of expression of the activin/
BMP antagonists follistatin (FST) and HTRA1 (PRSS11) (Fig.
5C and Table 1), pointing to inhibition of TGFβ signaling by
the HH/GLI pathway. Notably, FSTwas specifically induced by
GLI2, while HTRA1 responded to both GLI1 and GLI2ΔN.
This correlates well with the expression of follistatin mRNA in
mouse skin in the ORS of the hair follicle and in the basal layer
of the epidermis [70]. In follistatin-deficient mice, hair follicle
development is significantly retarded, while the number of hair
follicles in wild-type embryonic skin explants treated with
follistatin is increased [71]. Furthermore, the activators of
TGFβ signaling, BMP2 and BMP7, were downregulated by
GLI2, as was their target gene ID1 (Table 1) [72–74], a basic
helix–loop–helix transcription factor involved in mediating the
effect of TGFβ. TGFβ receptor2 (TGFBR2) is also down-
regulated. Together, these results point to an inhibitory role of
GLI2 on TGFβ signaling in hair follicle development.
Conclusions
Target gene expression after induction of GLI1 and GLI2 in
HaCaT keratinocytes illustrates the proliferation enhancing
Table 1
Gene expression profiles of human epidermal cells in response to GLI1 and GLI2ΔN
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Table 1 (continued)
Genes differentially expressed are sorted by fold induction/repression values of the GLI2ΔN 72-h time point. Gene names represent approved gene symbols according to
the HUGO Gene Nomenclature Committee (http://www.gene.ucl.ac.uk/nomenclature). Genes without a HUGO gene name are written in italic. Genes named “None”
represent Incyte EST sequences, which do not show any significant match with annotated nucleotide sequences in the GenBank/GenPept databases. Pathway ID
numbers refer to Fig. 4. White background, induced gene; gray background, repressed gene; light face, gene significant at fold-change ≥1.5; bold face, gene significant
at fold-change ≥2.0; –, no significant value.
a Resequenced EST clone.
b Verified by QRT-PCR.
Fig. 2. Changes in gene expression after induction of GLI1 or GLI2ΔN by
tetracycline in HaCaT keratinocytes. Venn diagram of the array data comparing
the inducing and repressing activities of GLI1 and GLI2ΔN. Genes changing
≥2.0-fold in response to GLI1 or expression after 24 and 72 h were included.
The total number of genes induced or repressed by each transcription factor is
indicated below.
627T. Eichberger et al. / Genomics 87 (2006) 616–632and differentiation-opposing effects of the two oncogenic
transcription factors. The identity of differentially expressed
genes reflects the activity of signaling pathways previously
implicated in keratinocyte and hair follicle differentiation. The
data support the view that GLI transcription factors have
overlapping yet distinct activities. There are clear quantitative
differences in the effects of the two transcription factors on a
small number of positively regulated genes such as TNC, FST,
and BCL2 (Figs. 5B and 5C). The activated form of GLI2,
GLI2ΔN, effects massive target gene repression, whereas only
weak repression is seen with GLI1 expression. Phosphoryla-
tion of GLI2 by PKA without evidence for proteolytic
processing favors the interpretation that no Ci/GLI3-like
product is responsible for the repression of most GLI2 target
genes. These results suggest that GLI2ΔN may specifically
activate the transcription of a repressor, which would then act
Fig. 3. GLI1 and GLI2ΔN are phosphorylated in the presence of forskolin, but not proteolytically processed. (A) Immunoprecipitation (IP) showing phosphorylation
of GLI1 and GLI2ΔN by protein kinase A (PKA) upon forskolin (FSK) treatment. GLI1 and GLI2ΔN were immunoprecipitated from FSK-treated cells expressing
GLI1 (GLI1 HaCaT) or GLI2ΔN (GLI2ΔN HaCaT) using GLI-specific antibodies (G1-C18, G2-N20) or normal goat IgG. Phosphorylated GLIs were visualized with
a primary antibody recognizing phosphorylated PKA sites (PKA substrate Ab) (top) and anti GLI antibodies (bottom). (B) No lower molecular bands of GLI1 or
GLI2ΔN protein were observed in GLI1 HaCaT or GLI2ΔN HaCaT cells upon FSK treatment. Total lysates of tetracycline-induced cells grown for 48 h in the
presence of FSK and controls were analyzed by Western blot using specific antibodies recognizing GLI1 and GLI2. Nonspecific signals are marked by asterisks.
628 T. Eichberger et al. / Genomics 87 (2006) 616–632on target genes. Alternatively or additionally, other modifica-
tions of GLI2 or interactions with other GLI molecules [22] or
unrelated further factors may result in gain of repressive
activity. A more comprehensive picture of the mechanism of
the overlaps and specificities of the GLI proteins will emerge
from the clarification of these issues.Fig. 4. Functional clustering of up- and downregulated genes. Clustering of arr
pathwayexplorer.genome.tugraz.at/). Grouping of genes refers to the GenMapp pathw
were mapped to 41 pathways or functional groups (see Table 1); for the remaining ge
pathway (total of 345 hits). Groups with fewer than 4 members are pooled in “others
front of each gene group denote the pathway ID as shown in Table 1.Material and methods
Cell cultures
HaCaT cells were cultured in Dulbecco's modified Eagle medium (pH 7.2,
high glucose; Invitrogen Life Technologies) supplemented with 10% fetal calf
serum (Invitrogen Life Technologies), 100 μg/ml streptomycin, and 62.5 μg/mlay data was carried out using the Pathway explorer software (https://www.
ay or functional group classification. 196 of 456 differentially expressed genes
nes no match was found. Most of the 196 genes gave matches in more than one
.” The number of hits found in each group is shown in parentheses. Numbers in
Fig. 5. Expression patterns of representative GLI1 and GLI2ΔN target genes. Induction of target genes was measured by QRT-PCR. Fold change refers to the ratios
of RNA from cells induced with tetracycline for the times indicated to uninduced cells. (A) Genes with similar expression patterns in response to GLI1 and
GLI2ΔN overexpression. (B) Genes preferentially induced by GLI1. (C) Genes preferentially induced by GLI2ΔN. (D) Genes preferentially repressed by
GLI2ΔN.
629T. Eichberger et al. / Genomics 87 (2006) 616–632penicillin (Sigma–Aldrich) at 37°C, 5% CO2. For PKA activation, forskolin (in
EtOH) (Sigma–Aldrich) was added to a final concentration of 10 μM. Controls
were treated with EtOH only.
Double stable inducible HaCaT lines expressing either human GLI1 (GLI1
HaCaT) or GLI2ΔN tagged with a 6×HIS epitope (GLI2ΔN HaCaT) [43]
were grown in the presence of 25 μg/ml zeocin (Invitrogen Life Technology)
and 8 μg/ml Blasticidin-S (ICN-Biomedica). Transgene expression was
induced by adding 1 μg/ml tetracycline (Tet) (Invitrogen Life Technologies)
to the medium.Table 2




12 h+Tet fI/R (±SD) 24 h+Tet fI/R (±SD) 72 h+Tet fI/R (±S
CCNA2 0.97 (±0.044) 0.86 (±0.101) 7.49 (±0.127)
CDC2 1.10 (±0.133) 1.07 (±0.151) 6.07 (±0.515)
CDC45L 1.17 (±0.277) 2.64 (±0.068) 13.39 (±0.808)
E2F1 1.17 (±0.071) 3.45 (±0.179) 4.96 (±0.069)
CCNB1 1.27 (±0.313) 1.24 (±0.215) 4.84 (±0.625)
CKS1B 0.93 (±0.030) 1.35 (±0.082) 3.54 (±0.878)
CCNE 0.86 (±0.085) 1.80 (±0.069) 1.49 (±0.288)
CDKN1A 0.99 (±0.072 0.52 (±0.028) 0.71 (±0.039
KRT1 1.27 (±0.048) 0.81 (±0.050) 0.67 (±0.286)
KRT10 0.83 (±0.079) 0.55 (±0.030) 0.45 (±0.088)
IVL 0.80 (±0.041) 0.56 (±0.018) 0.32 (±0.025)
PI3 0.83 (±0.041) 0.37 (±0.013) 0.25 (±0.044)
SPRR2A 0.82 (±0.206) 0.49 (±0.068) 0.34 (±0.177)
Ratios and SD were calculated from the average of four real-time RT-PCR measurePreparation of 33P-labeled cDNA
Total RNA was extracted with TRI reagent (Molecular Research Center)
according to the manufacturer's instructions followed by LiCl precipitation. To
eliminate differences between clonal cell lines, RNA from four independently
isolated lines expressing either GLI1 or GLI2ΔN was pooled for cDNA array
analysis. cDNA labeling was carried out as described previously [75]. In brief,
15 μg pooled total RNAwas reverse transcribed with Superscript II (Invitrogen
Life Technologies) in the presence of 70 μCi [α-33P]dCTP (3000 Ci/mmol;GLI2ΔN HaCaT
D) 12 h+Tet fI/R (±SD) 24 h+Tet fI/R (±SD) 72 h+Tet fI/R (±SD)
0.98 (±0.039) 1.46 (±0.166) 5.63 (±0.437)
1.06 (±0.039) 1.18 (±0.137) 5.59 (±0.271)
0.85 (±0.093) 2.39 (±0.398) 14.39 (±0.747)
0.64 (±0.013) 3.99 (±0.097) 9.85 (±0.102)
1.03 (±0.046) 0.85 (±0.103) 4.84 (±0.351)
1.04 (±0.054) 1.26 (±0.087) 4.96 (±0.394)
0.82 (±0.010) 1.74 (±0.024) 4.11 (±0.107)
0.56 (±0.010) 0.32 (±0.020 0.38 (±0.054
1.00 (±0.323) 0.15 (±0.006) 0.04 (±0.019)
0.98 (±0.267) 0.09 (±0.001) 0.01 (±0.005)
1.21 (±0.623) 0.25 (±0.041) 0.04 (±0.002)
1.25 (±0.222) 0.20 (±0.024) 0.10 (±0.027)
1.15 (±0.837) 0.18 (±0.005) 0.05 (±0.003)
ments.
630 T. Eichberger et al. / Genomics 87 (2006) 616–632Amersham Biosciences). Labeled cDNA was purified with GFX DNA
purification columns (Amersham Biosciences) and equal counts of labeled
cDNA were added to each hybridization.
High-density DNA filter array production and hybridization
The Human Drug Discovery clone set (10,000 sequence-verified ESTs) and
a selection of 2000 sequence-verified EST clones from the human UniGem
version 2.0 library were obtained from Incyte Genomics. Both sets were
amplified by PCR, spotted, and hybridized separately with labeled cDNA. PCR
amplification, array production, and hybridization were done as described
previously [60,75]. Arrays were exposed for 4 days and scanned with a BAS-
1800II (Fuji) phosphorimager. Array images were analyzed using the AIDA
Metrix suite (Raytest). Data from two independent hybridizations were collected
at each time point. Data were normalized by total signal intensity and the
statistical significance was analyzed using the SAM software package [48].
Only genes showing at least a 2-fold change in expression were called
significant. For genes reaching this threshold at one time point, further points
were analyzed also at 1.5-fold change.
The data discussed in this publication have been deposited in the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are acces-
sible through GEO Series Accession No. GSE 1434.
QRT-PCR analysis
RNA prepared as described above was further purified with the High Pure
RNA isolation kit (Roche) to remove any genomic contamination. cDNA was
synthesized from 4 μg purified total RNAwith Superscript II (Invitrogen) using
oligo(dT) primers, according to the manufacturer's instructions. QRT-PCR
analysis was performed on a Rotorgene 2000 (Corbett Research) using iQTM
SYBR Green Supermix (Bio-Rad). Primer sequences not published previously
[43,60] are shown in Table 3 (supplementary material). Large ribosomal protein
P0 (RPLP0) was used as a reference in all QRT-PCR analyses [76].
Immunoprecipitation and Western blot analysis
GLI1 HaCaT and GLI2ΔN HaCaT cells were lysed 24 h after Tet induction
in RIPA buffer (150 mMNaCl, 0.1% SDS, 10 mM Tris–HCl, pH 7.4, 1% Triton
X-100, 1% sodium deoxycholate, 1 mM PMSF, 1 mM protease inhibitor mix
(Sigma–Aldrich)) at 4°C. Lysates were cleared by centrifugation (15 min,
13,000 rpm, 4°C) and incubated overnight with the appropriate antibody at 4°C.
After incubation with protein G–Sepharose (Amersham Biosciences) for 2 h at
4°C, the Sepharose was washed four times with RIPA buffer and proteins were
eluted in hot lysis buffer (125 mM Tris (pH 6.8), 5% glycerol, 2% SDS, 1% β-
mercaptoethanol, 0.006% bromophenol blue) and resolved by SDS–PAGE.
SDS–PAGE and Western blotting were performed according to standard
protocols. Primary and secondary antibodies used were goat polyclonal anti-
GLI2 (GLI2 N20; Santa Cruz), goat polyclonal anti-GLI1 (GLI1 C18; Santa
Cruz), rabbit anti-phospho-(Ser/Thr) PKA substrate antibody (Cell Signaling
Technologies), anti-rabbit IgG–HRP (Santa Cruz), and rabbit anti-goat IgG–
HRP (Chemicon).
Luciferase reporter assay
HaCaTcells were grown in 12-well plates to 80% confluence and transfected
in triplicate with GLI1, GLI2ΔN [43], GLI2 [34], and Renilla luciferase (pRL-
SV40 (Promega)) expression plasmids and pGL3 luciferase reporter plasmids as
indicated in Fig. 1B. Cells were harvested 48 h after transfection and luciferase
activity was measured with a Lucy II luminometer (Anthos) using the dual-
luciferase reporter assay system (Promega) according to the manufacturer's
instructions. Data were normalized for Renilla luciferase activity.
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